Synthesis of new series of quinoline derivatives with insecticidal effects on larval vectors of malaria and dengue diseases

Mosquito borne diseases are on the rise because of their fast spread worldwide and the lack of effective treatments. Here we are focusing on the development of a novel anti-malarial and virucidal agent with biocidal effects also on its vectors. We have synthesized a new quinoline (4,7-dichloroquinoline) derivative which showed significant larvicidal and pupicidal properties against a malarial and a dengue vector and a lethal toxicity ranging from 4.408 mu M/mL (first instar larvae) to 7.958 mu M/mL (pupal populations) for Anopheles stephensi and 5.016 mu M/mL (larva 1) to 10.669 mu M/mL (pupae) for Aedes aegypti. In-vitro antiplasmodial efficacy of 4,7-dichloroquinoline revealed a significant growth inhibition of both sensitive strains of Plasmodium falciparum with IC50 values of 6.7 nM (CQ-s) and 8.5 nM (CQ-r). Chloroquine IC50 values, as control, were 23 nM (CQ-s), and 27.5 nM (CQ-r). In vivo antiplasmodial studies with P. falciparum infected mice showed an effect of 4,7-dichloroquinoline compared to chloroquine. The quinoline compound showed significant activity against the viral pathogen serotype 2 (DENV-2). In vitro conditions and the purified quinoline exhibited insignificant toxicity on the host system up to 100 mu M/mL. Overall, 4,7-dichloroquinoline could provide a good anti-vectorial and anti-malarial agent.

Automated summary

Mosquito borne diseases are a global concern due to their fast spread and the lack of effective treatments. This study focuses on the development of a novel compound that can act as an anti-malarial and anti-viral agent while also targeting the vectors. The synthesized quinoline derivative showed significant larvicidal and pupicidal properties against malaria and dengue vectors, as well as potent antiplasmodial activity against sensitive strains of Plasmodium falciparum.